The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy (iADT) with relugolix.
 
Patrick Campbell
No Relationships to Disclose
 
Georges Gebrael
No Relationships to Disclose
 
Arshit Narang
No Relationships to Disclose
 
Chadi Hage Chehade
No Relationships to Disclose
 
Vinay Mathew Thomas
No Relationships to Disclose
 
Gliceida Galarza Fortuna
No Relationships to Disclose
 
Nicolas Sayegh
No Relationships to Disclose
 
Nishita Tripathi
No Relationships to Disclose
 
Clara Tandar
No Relationships to Disclose
 
Emre Dal
No Relationships to Disclose
 
Haoran Li
No Relationships to Disclose
 
Umang Swami
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Exelixis; Imvax; Pfizer; Sanofi; Seagen
Research Funding - Exelixis (Inst); Janssen (Inst); Seattle Genetics/Astellas (Inst)
 
Neeraj Agarwal
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Exelixis; Pfizer
 
Benjamin L. Maughan
Consulting or Advisory Role - Astellas Medivation; AVEO; Bavarian Nordic; Bayer; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Janssen Oncology; Merck; Peloton Therapeutics; Pfizer; Tempus
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Exelixis (Inst)
Travel, Accommodations, Expenses - Exelixis